Lisata Therapeutics (NASDAQ:LSTA) Shares Down 0.9% – What’s Next?

Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) dropped 0.9% on Thursday . The stock traded as low as $3.30 and last traded at $3.33. Approximately 13,041 shares traded hands during trading, a decline of 83% from the average daily volume of 76,951 shares. The stock had previously closed at $3.36.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LSTA. Zacks Research raised Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Tuesday, April 21st. Finally, HC Wainwright cut shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Lisata Therapeutics presently has an average rating of “Reduce” and a consensus price target of $15.00.

Lisata Therapeutics Price Performance

The firm’s 50 day simple moving average is $3.33 and its 200-day simple moving average is $3.66. The company has a market cap of $30.34 million, a price-to-earnings ratio of -1.79 and a beta of 0.79.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Monday, May 11th. The company reported ($0.50) EPS for the quarter. On average, analysts forecast that Lisata Therapeutics, Inc. will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Lisata Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cerity Partners LLC acquired a new stake in shares of Lisata Therapeutics in the second quarter valued at approximately $32,000. CIBC Bancorp USA Inc. acquired a new position in shares of Lisata Therapeutics in the 3rd quarter valued at $37,000. Ground Swell Capital LLC raised its position in Lisata Therapeutics by 64.0% in the 4th quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock valued at $73,000 after purchasing an additional 15,213 shares during the last quarter. Renaissance Technologies LLC raised its position in Lisata Therapeutics by 6.1% in the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after purchasing an additional 7,093 shares during the last quarter. Finally, Deltec Asset Management LLC purchased a new stake in Lisata Therapeutics in the 1st quarter valued at $451,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.